Novel peptide ligands with dual acting pharmacophores designed for the pathophysiology of neuropathic pain

Brain Research

Volumn 1395, Issue , 2011, Pages 1-11

  Hanlon, Katherine E ^a   Herman, Dave S ^a   Agnes, Richard S ^b   Largent Milnes, Tally M ^a   Kumarasinghe, Isuru R ^b   Ma, Sho W ^a   Guo, Wenhong ^a   Lee, Yeon Sun ^a,b   Ossipov, Michael H ^a   Hruby, Victor J ^b   Lai, Josephine ^a   Porreca, Frank ^a   Vanderah, Todd W ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b University of Arizona   (United States)

Author keywords

Cholecystokinin; Neuropathic pain; Opioids; Spinal nerve ligation

Indexed keywords

ANALGESIC AGENT; CHOLECYSTOKININ; CHOLECYSTOKININ RECEPTOR; GABAPENTIN; MORPHINE; OPIATE RECEPTOR; RSA 504; RSA 601; TYROSYL DEXTRO NORLEUCYLGLYCYLTRYPTOPHYLNORLEUCYLASPARTYLPHENYLALANINAMIDE; TYROSYL DEXTRO PHENYLALANYLGLYCYL DEXTRO TRYPTOPHYLNORLEUCYL N METHYL ESTER ASPARTYLPHENYLALANINAMIDE; UNCLASSIFIED DRUG;

ALLODYNIA; ANALGESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DOSE RESPONSE; HYPERALGESIA; MALE; MOTOR DYSFUNCTION; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; PAIN THRESHOLD; PHARMACOPHORE; PRIORITY JOURNAL; RAT; SEDATION;

ANALGESICS, OPIOID; ANIMALS; DISEASE MODELS, ANIMAL; DRUG DESIGN; MALE; NEURALGIA; NEUROPEPTIDES; OLIGOPEPTIDES; PERIPHERAL NERVOUS SYSTEM DISEASES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CHOLECYSTOKININ A; RECEPTOR, CHOLECYSTOKININ B; RECEPTORS, NEUROPEPTIDE; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, MU;

RATTUS;

EID: 79957882036     PISSN: 00068993     EISSN: 00068993     Source Type: Journal    
DOI: 10.1016/j.brainres.2011.04.024     Document Type: Article

References (56)

1. Afrah, A.W., Gustafsson, H., Olgart, L., Brodin, E., Stiller, C.O., 2001. Changes in spinal cholecystokinin release after peripheral axotomy. Neuroreport. 12, 49-52. (Pubitemid 32099026)
2. Agnes, R.S., Ying, J., Kover, K.E., Lee, Y.S., Davis, P., Ma, S.W., Badghisi, H., Porreca, F., Lai, J., Hruby, V.J., 2008. Structure-activity relationships of bifunctional cyclic disulfide peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. Peptides. 29, 1413-1423.
3. Becker, C., Pohl, M., Thiebot, M.-H., Collin, E., Hamon, M., Cesslin, F., Benoliel, J.-J., 2000. δ-opioid receptor-mediated increase in cortical extracellular levels of cholecystokinin-like material by subchronic morphine in rats. Neuropharmacology. 39, 161-171. (Pubitemid 30009810)
4. Behbehani, M.M., 1995. Functional characteristics of the midbrain periaqueductal gray. Prog Neurobiol. 46, 575-605.
5. Breivik, H., Collett, B., Ventafridda, V., Cohen, R., Gallacher, D., 2006. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 10, 287-333.
6. Chaplan, S.R., Bach, F.W., Pogrel, J.W., Chung, J.M., Yaksh, T.L., 1994. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods. 53, 55-63. (Pubitemid 24238751)
7. Cho, H.J., Basbaum, A.I., 1991. GABAergic circuitry in the rostral ventral medulla of the rat and its relationship to descending antinociceptive controls. Journal of Comparative Neurology. 303, 316-328.
8. Colpaert, F.C., 1996. System theory of pain and of opiate analgesia: no tolerance to opiates. Pharmacol Rev. 48, 355-402. (Pubitemid 26325802)
9. Dourish, C.T., O'Neill, M.F., Coughlan, J., Kitchener, S.J., Hawley, D., Iversen, S.D., 1990. The selective CCK-B receptor antagonist L-365,260 enhances morphine analgesia and prevents morphine tolerance in the rat. Eur J Pharmacol. 176, 35-44. (Pubitemid 20035551)
10. Frampton, J.E., 2010. Tapentadol immediate release: a review of its use in the treatment of moderate to severe acute pain. Drugs. 70, 1719-1743.
11. Friedrich, A.E., Gebhart, G.F., 2003. Modulation of visceral hyperalgesia by morphine and cholecystokinin from the rat rostroventral medial medulla. Pain. 104, 93-101. (Pubitemid 36835878)
12. Ghilardi, J.R., Allen, C.J., Vigna, S.R., McVey, D.C., Mantyh, P.W., 1992. Trigeminal and dorsal root ganglion neurons express CCK receptor binding sites in the rat, rabbit, and monkey: possible site of opiate-CCK analgesic interactions. J Neurosci. 12, 4854-4866.
13. Gilbert, A.K., Franklin, K.B., 2001. GABAergic modulation of descending inhibitory systems from the rostral ventromedial medulla (RVM). Dose-response analysis of nociception and neurological deficits. Pain 90, 25-36.
14. Gustafsson, H., Afrah, A.W., Stiller, C.O., 2001. Morphine-induced in vivo release of spinal cholecystokinin is mediated by deltaopioid receptors - effect of peripheral axotomy. J Neurochem. 78, 55-63. (Pubitemid 32622588)
15. Hargreaves, K., Dubner, R., Brown, F., Flores, C., Joris, J., 1988. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain. 32, 77-88.
16. Heinricher, M.M., Haws, C.M., Fields, H.L., 1991. Evidence for GABA-mediated control of putative nociceptive modulating neurons in the rostral ventromedial medulla: iontophoresis of bicuculline eliminates the off-cell pause. Somatosens Mot Res. 8, 215-225.
17. Heinricher, M.M., Neubert, M.J., 2004. Neural basis for the hyperalgesic action of cholecystokinin in the rostral ventromedial medulla. J Neurophysiol. 92, 1982-1989. (Pubitemid 39298656)
18. Hruby, V., Fang, S.-N., Kramer, T., Davis, P., Parkhurst, D., Nikiforovish, G., Boteju, L., Slaminova, J., Yamamura, H., Burks, T., 1994. Analogues of cholecystokinin26-33 selective for B-type CCK receptors possess delta opioid receptor agonist activity in vitro and in vivo: evidence for similarities in CCK-B and delta opioid receptor requirements. In peptides: Chemistry, Structure and Biology. Vol., R. Hodges, J. Smith, ed. eds. ESCOM Publishers, Leiden, pp. 669-671.
19. Hruby, V.J., Agnes, R.S., Davis, P., Ma, S.W., Lee, Y.S., Vanderah, T.W., Lai, J., Porreca, F., 2003. Design of novel peptide ligands which have opioid agonist activity and CCK antagonist activity for the treatment of pain. Life Sci. 73, 699-704. (Pubitemid 36703264)
20. Jensen, T.S., Gottrup, H., Sindrup, S.H., Bach, F.W., 2001. The clinical picture of neuropathic pain. Eur J Pharmacol. 429, 1-11. (Pubitemid 33043977)
21. Kim, S.H., Chung, J.M., 1992. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain. 50, 355-363.
22. Kovelowski, C.J., Ossipov, M.H., Sun, H., Lai, J., Malan, T.P., Porreca, F., 2000. Supraspinal cholecystokinin may drive tonic descending facilitation mechanisms to maintain neuropathic pain in the rat. Pain. 87, 265-273. (Pubitemid 30645875)
23. Laulin, J.P., Larcher, A., Celerier, E., Le Moal, M., Simonnet, G., 1998. Long-lasting increased pain sensitivity in rat following exposure to heroin for the first time. Eur J Neurosci. 10, 782-785. (Pubitemid 28325504)
24. Laulin, J.P., Celerier, E., Larcher, A., Le Moal, M., Simonnet, G., 1999. Opiate tolerance to daily heroin administration: an apparent phenomenon associated with enhanced pain sensitivity. Neuroscience. 89, 631-636. (Pubitemid 29070990)
25. Lezoualc'h, F., Jockers, R., Berque-Bestel, I., 2009. Multivalent-based drug design applied to serotonin 5-HT(4) receptor oligomers. Curr Pharm Des. 15, 719-729.
26. Loeser, J.D., Bonica, J.J., 2001. Bonica's management of pain. Vol., Lippincott Williams & Wilkins, Philadelphia, Penn.
27. Lorenzen, A., Fuss, M., Vogt, H., Schwabe, U., 1993. Measurement of guanine nucleotide-binding protein activation by A1 adenosine receptor agonists in bovine brain membranes: stimulation of guanosine-5′-O-(3-[35S]thio) triphosphate binding. Mol Pharmacol. 44, 115-123. (Pubitemid 23230467)
28. Mao, J., Price, D.D., Mayer, D.J., 1994. Thermal hyperalgesia in association with the development of morphine tolerance in rats: roles of excitatory amino acid receptors and protein kinase C. Journal of Neuroscience. 14, 2301-2312. (Pubitemid 24108135)
29. Mao, J., Price, D.D., Mayer, D.J., 1995. Mechanisms of hyperalgesia and morphine tolerance: a current view of their possible interactions. Pain. 62, 259-274.
30. Mason, P., 2001. Contributions of the medullary raphe and ventromedial reticular region to pain modulation and other homeostatic functions. Annu Rev Neurosci. 24, 737-777. (Pubitemid 32695244)
31. McCleane, G.J., 1998. The cholecystokinin antagonist proglumide enhances the analgesic efficacy of morphine in humans with chronic benign pain. Anesth Analg. 87, 1117-1120. (Pubitemid 28501169)
32. McCleane, G.J., 2002. A phase 1 study of the cholecystokinin (CCK) B antagonist L-365,260 in human subjects taking morphine for intractable non-cancer pain. Neurosci Lett. 332, 210-212. (Pubitemid 35223482)
33. McCleane, G.J., 2003. A randomised, double blind, placebo controlled crossover study of the cholecystokinin 2 antagonist L-365,260 as an adjunct to strong opioids in chronic human neuropathic pain. Neurosci Lett. 338, 151-154. (Pubitemid 36140159)
34. Merskey, H., 2002. Clarifying definition of neuropathic pain. Pain. 96, 408-409.
35. Moreau, J.L., Fields, H.L., 1986. Evidence for GABA involvement in midbrain control of medullary neurons that modulate nociceptive transmission. Brain Research. 397, 37-46. (Pubitemid 17184823)
36. Nichols, M.L., Bian, D., Ossipov, M.H., Malan Jr., T.P., Porreca, F., 1996. Antiallodynic effects of a CCKB antagonist in rats with nerve ligation injury: role of endogenous enkephalins. Neurosci Lett. 215, 161-164. (Pubitemid 26323451)
37. Ossipov, M.H., Lai, J., Malan, T.P.J., Porreca, F., 2000. Spinal and supraspinal mechanisms of neuropathic pain. Annals of the New York Academy of Sciences. 909, 12-24. (Pubitemid 30462030)
38. Ossipov, M.H., Porreca, F., 2005. Challenges in the development of novel treatment strategies for neuropathic pain. NeuroRx. 2, 650-661. (Pubitemid 41393272)
39. Raynauld, J.P., Martel-Pelletier, J., Abram, F., Dorais, M., Haraoui, B., Choquette, D., Bias, P., Emmert, K.H., Laufer, S., Pelletier, J.P., 2008. Analysis of the precision and sensitivity to change of different approaches to assess cartilage loss by quantitative MRI in a longitudinal multicentre clinical trial in patients with knee osteoarthritis. Arthritis Res Ther. 10, R129.
40. Roberts, J., Ossipov, M.H., Porreca, F., 2009. Glial activation in the rostroventromedial medulla promotes descending facilitation to mediate inflammatory hypersensitivity. Eur J Neurosci. 30, 229-241.
41. Slaninova, J., Knapp, R.J., Wu, J.J., Fang, S.N., Kramer, T., Burks, T.F., Hruby, V.J., Yamamura, H.I., 1991. Opioid receptor binding properties of analgesic analogues of cholecystokinin octapeptide. Eur J Pharmacol. 200, 195-198.
42. Tallarida, R.J., Murray, R.B., 1987. Manual of Pharmacological Calculations with Computer Programs. Springer-Verlag Publishers, New York, NY, Vol.
43. Trujillo, K.A., Akil, H., 1991. Opiate tolerance and dependence: recent findings and synthesis. New Biologist. 3, 915-923.
44. Urban, M.O., Gebhart, G.F., 1999. Supraspinal contributions to hyperalgesia. Proc Natl Acad Sci U S A. 96, 7687-7692. (Pubitemid 29328341)
45. Vanderah, T.W., Gardell, L.R., Burgess, S.E., Ibrahim, M., Dogrul, A., Zhong, C.M., Zhang, E.T., Malan Jr., T.P., Ossipov, M.H., Lai, J., Porreca, F., 2000. Dynorphin promotes abnormal pain and spinal opioid antinociceptive tolerance. J Neurosci. 20, 7074-7079.
46. Vanderah, T.W., Largent-Milnes, T., Lai, J., Porreca, F., Houghten, R. A., Menzaghi, F., Wisniewski, K., Stalewski, J., Sueiras-Diaz, J., Galyean, R., Schteingart, C., Junien, J.L., Trojnar, J., Riviere, P.J., 2008. Novel D-amino acid tetrapeptides produce potent antinociception by selectively acting at peripheral kappa-opioid receptors. Eur J Pharmacol. 583, 62-72.
47. Wiesenfeld-Hallin, Z., Xu, X.J., Hokfelt, T., 2002. The role of spinal cholecystokinin in chronic pain states. Pharmacol Toxicol. 91, 398-403. (Pubitemid 36138721)
48. Wild, J.E., Grond, S., Kuperwasser, B., Gilbert, J., McCann, B., Lange, B., Steup, A., Haufel, T., Etropolski, M.S., Rauschkolb, C., Lange, R., 2010. Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Pract. 10, 416-427.
49. Williams, C., Rosenfeld, G., Dafney, N., Fang, S.-N., Hruby, V., Bowden, G., Cullinan, C., Burks, T., 1994. SNF9007: a novel analgesic that acts simultaneously at delta-1, delta-2, and mu opioid receptors. Journal of Pharmacology And Experimental Therapeutics. 269, 750-755. (Pubitemid 24157346)
50. Woodcock, J., Witter, J., Dionne, R.A., 2007. Stimulating the development of mechanism-based, individualized pain therapies. Nat Rev Drug Discov. 6, 703-710. (Pubitemid 47338179)
51. Woolf, C.J., 1981. Intrathecal high dose morphine produces hyperalgesia in the rat. Brain Research. 209, 491-495. (Pubitemid 11137041)
52. Wright, A., Luedtke, K.E., Vandenberg, C., 2011. Duloxetine in the treatment of chronic pain due to fibromyalgia and diabetic neuropathy. J Pain Res. 4, 1-10.
53. Xie, J.Y., Herman, D.S., Stiller, C.O., Gardell, L.R., Ossipov, M.H., Lai, J., Porreca, F., Vanderah, T.W., 2005. Cholecystokinin in the rostral ventromedial medulla mediates opioid-induced hyperalgesia and antinociceptive tolerance. J Neurosci. 25, 409-416. (Pubitemid 40105611)
54. Yaksh, T.L., Rudy, T.A., 1976. Chronic catheterization of the spinal subarachnoid space. Physiol Behav. 17, 1031-1036. (Pubitemid 8063691)
55. Yaksh, T.L., Harty, G.J., 1988. Pharmacology of the allodynia in rats evoked by high dose intrathecal morphine. Journal of Pharmacology & Experimental Therapeutics. 244, 501-507. (Pubitemid 18076587)
56. Zhang, W., Gardell, S., Zhang, D., Xie, J.Y., Agnes, R.S., Badghisi, H., Hruby, V.J., Rance, N., Ossipov, M.H., Vanderah, T.W., Porreca, F., Lai, J., 2009. Neuropathic pain is maintained by brainstem neurons co-expressing opioid and cholecystokinin receptors. Brain. 132, 778-787.